Read our research. Examine our quality.
Since Medical Energetics was founded, we have been committed to building and continually improving upon a firm foundation of research. Our products are science-based, clinically proven and reliable. While our research provides solid scientific support for our products, it also informs our understanding of the technology’s potential and lays the groundwork for product innovation and development.
Over the past six years, Medical Energetics has built a body of foundational studies on the DHC technology involving both humans and animals. Pre-clinical and phase 1 clinical studies have yielded promising results.
Stem Cell Applications
Initial investigations began with an examination of how the DHC coil might affect the regenerative capabilities of planarian, a type of flatworm. Planarian were transversally cut and monitored against a control group for rates of complete regeneration. Repeated experiments demonstrated that specific configurations and settings of the DHC improved planarians' natural regenerative capabilities. While planarian typically take 5 to 17 days to regenerate (depending on type), exposure to the DHC in these initial experiments reduced the regeneration timeframe to less than a day.
In another study that is currently underway with the Remedi Regenerative Medicine Institute in Ireland, Medical Energetics is exploring the effect of the DHC on primary human mesenchymal stem cells (hMSCs). Scientists are interested in hMSCs as a novel treatment to support diabetic wound healing. The DHC may enhance the proliferation and/or the function of mesenchymal stem cells for therapy, thereby making their application significantly more successful. Study results to date are promising, showing evidence of an effect on certain donor cells.
Medical Energetics completed two IRB approved open label phase 1 clinical studies, each with populations of 15 individuals, to evaluate the effects of the DHC on symptoms of diabetic neuropathy. Patients experienced up to 70 percent improvement in many of their symptoms including sensation, pain and evidence of increased blood flow. These initial studies indicate the potential for this device to provide one effective, 30-minute treatment per week, for eight weeks.
Medical Energetics also examined the effect of the DHC magnetic field on nerve regeneration, using ATP induced neurite outgrowth from cultured PC12 cells as a model. Study investigators monitored changes in the shape of cells visually at various points in the experiment. Results showed that, in the presence of low concentrations of ATP, the DHC field significantly increased neurite outgrowth in the cultured cells.
Two open label clinical studies on patients suffering with pain caused by diabetic neuropathy has shown that our technology can reduce inflammation and relieve pain within minutes of application.